Home › All Companies › BNGO › Annual Report

Bionano Genomics, Inc. (BNGO) — Annual Report

AI-Powered SEC Filing Analysis

← All BNGO filings
Latest Annual Report Filed: 2026-03-23

Key Insights

  • Bionano Genomics reported a significant increase in convertible debt and warrants, indicating potential dilution for shareholders.
  • The company disclosed plans for a workforce reduction, which could impact future operations and growth.
  • Bionano's revenue from the Americas region, its primary market, showed a notable decline year-over-year, raising concerns about sales performance.
Sentiment: Negative Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-23. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Bionano Genomics, Inc.

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.